Advancing Myeloma Treatment With Blood-Based MRD Testing
In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.
Next Steps for Using MRD to Guide Maintenance Therapy for Multiple Myeloma
Ben Derman, MD, discusses next steps for using minimal residual disease-guided discontinuation of maintenance therapy in patients with multiple myeloma.
Higher MRD Threshold Could Guide Discontinuation of Myeloma Maintenance
Ben Derman, MD, discussed results from a trial investigating minimal residual disease–guided discontinuation of maintenance therapy in patients with multiple myeloma.
Goals of an MRD-Based Discontinuation Trial in Multiple Myeloma
Ben Derman, MD, discussed the rationale for an ongoing clinical trial evaluating minimal residual disease–guided discontinuation of maintenance therapy in patients with multiple myeloma.